The Brewster Laboratory (email@example.com) is interested in determining the effect of altered biomechanics and extracellular matrix formation during arterial remodeling after vascular intervention in stiffened and diseased arteries. Using animal models and human arterial tissue, I quantify the in and ex vivo contribution of the cellular and extracellular matrix to biomechanical forces of the artery in stiffened and healthy states. In turn these forces manipulate the cellular and extracellular matrix composition of these arteries during remodeling, and this response is different in stiffened arteries, which are commonly encountered clinically. Thus understanding of this pathologic remodeling in model and human tissue is novel and critical to the development of intelligent therapeutics.
An engineer by training, Dr. Padala is currently focused on studying the biomechanics and mechanobiology of heart valve disease and heart failure. He received his BS in mechanical engineering from Osmania University in India in 2004, and an MS in mechanical engineering and PhD in bioengineering from Georgia Tech in 2010. Since joining Emory and establishing his independent laboratory in 2010, his focus has been on studying in-vivo heart valve and cardiac mechanics in pre-clinical models. In 2012, he spent one year at Imperial College London on a Leducq Fondation Career Development Award. He trained under Prof. Sir. Magdi Yacoub, a pioneer in cardiac transplantation and heart valve tissue engineering.
Heart Failure, Cardiac Valve Disease, Cardiovascular Devices, Cell and Gene Therapy, Tissue Engineering of Heart Valves
My laboratory is interested in the pathogenesis of heart valve disease and its impact on the onset and progression of heart failure. We use rodent and swine models of heart valve regurgitation, to understand the changes in the myocardial remodeling at multiple scales. Our recent work is also focused on linking functional changes in the myocardium to detectable genomic, transcriptomic, proteomic, and metabolomic changes, and investigate the potential of using their relationship for early detection of heart failure. Some of our work also involves developing new medical devices and technologies to repair heart valves and associated heart failure.
The Xu laboratory is focusing on human cardiomyocytes derived from pluripotent stem cells, which hold promise for cardiac cell therapy, disease modeling, drug discovery, and the study of developmental biology. The laboratory is also collaborating with investigators in Georgia Tech, Emory University, and Children's Healthcare of Atlanta, exploring the application of nanotechnology and tissue engineering in stem cell research.